Abstract 177P
Background
Ramcirumab (RAM) plus paclitaxel (PTX) is the standard second-line chemotherapy for metastatic gastric cancer. The ABSOLUTE trial showed that weekly nanoparticle albumin-bound (nab)-PTX was non-inferior to weekly PTX in terms of overall survival (OS). [Objective] This study aimed to evaluate the efficacy and safety of nab-PTX plus RAM compared with PTX plus RAM in metastatic gastric cancer patients, retrospectively.
Methods
Patients who received RAM plus nab-PTX or PTX in our institution from August 2015 to December 2018 were included in this retrospective study. (PTX plus RAM patients were administered from August 2015 to April 2018, and nab-PTX plus RAM patients received the combination from May 2018 to December 2018). Response rate, progression-free survival (PFS), OS and safety were assessed.
Results
A total of 79 patients were included in this study (24 in the nab-PTX plus RAM group and 55 in the PTX plus RAM group). Among the 17 patients with measurable lesions in the nab-PTX plus RAM group, 6 achieved PR (an objective response rate of 35%). Among the 38 patients with measurable lesions in the PTX plus RAM group, 8 achieved PR (an objective response rate of 21%). There was no significant difference between the two groups (p = 0.26), but nab-PTX plus RAM tended to produce a higher response rate than PTX plus RAM. The PFS was 5.7 months in the nab-PTX plus RAM group and 5.1 months in the PTX plus RAM group (p = 0.12). OS was not reached in the nab-PTX plus RAM group and was 8.6 months in the PTX plus RAM group (p = 0.27). The improvement rate of ascites did not differ between the two groups (38.4% in the nab-PTX plus RAM group and 40% in the PTX plus RAM group). Neutropenia was the most common grade 3 or 4 hematological toxicity, and there was no difference between the two groups (58.3% in the nab-PTX plus RAM group and 58.2% in the PTX plus RAM group). The incidence of any grade 3 or 4 non-hematological toxicity were also not different between the two groups.
Conclusions
This study suggests that nab-PTX plus RAM had almost similar efficacy and safety compared with PTX plus RAM in patients with metastatic gastric cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87P - Negative to positive lymph node ratio-prognostic marker of survival in node positive rectal cancer
Presenter: Pavan Jonnada
Session: Poster display session
Resources:
Abstract
88P - The Sidra LUMC advanced colon cancer NGS cohort
Presenter: Wouter Hendrickx
Session: Poster display session
Resources:
Abstract
89P - A phase II trial of adjuvant chemoradiotherapy for patients with high-risk rectal submucosal invasive cancer after local resection
Presenter: Masaaki Noguchi
Session: Poster display session
Resources:
Abstract
90P - High MICB expression confers prognostic benefit in colorectal cancer
Presenter: Shanchao Yu
Session: Poster display session
Resources:
Abstract
91P - Adjuvant therapy for high-risk stage II or stage III colon adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study
Presenter: Chien-Hsin Chen
Session: Poster display session
Resources:
Abstract
92P - Prospective randomized controlled study comparing primary surgery versus neoadjuvant chemotherapy followed by surgery in gastric carcinoma
Presenter: Vipin Goel
Session: Poster display session
Resources:
Abstract
93P - Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis
Presenter: Yijiao Chen
Session: Poster display session
Resources:
Abstract
94P - NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final analysis
Presenter: Michio Nakamura
Session: Poster display session
Resources:
Abstract
95P - Anatomical resections improve relapse-free survival in patients with KRAS/NRAS/BRAF- mutated colorectal liver metastases
Presenter: Ye Wei
Session: Poster display session
Resources:
Abstract
96P - Incidence, characteristics and prognosis in colorectal cancer with CNS metastases
Presenter: Nicola Taylor
Session: Poster display session
Resources:
Abstract